Semaglutide — research catalogue reference

Semaglutide is a synthetic analogue of human GLP-1, modified to resist enzymatic breakdown and extend its half-life. Its single-receptor profile is why it is used as the comparator in most dual- and triple-agonist research.

In Australia, prescription medicines containing semaglutide are separately regulated by the TGA. Material listed here is a laboratory reference material, not offered for human or veterinary use; see the compliance page for official TGA guidance.

The literature spans receptor binding and signalling assays, comparative agonist pharmacology, and clinical trial programmes run by the compound's developer.

We do not reproduce trial outcomes or endpoint figures. Use the PubMed link below to read the primary sources in full.

Aussie Peptides does not publish product- or lot-specific preparation, storage or stability data. Base preparation, storage and disposal on the supplier safety data sheet (SDS) and your institution's standard operating procedures.

Where a vial label shows a lot number and a batch report has been published for that lot, it can be looked up on the verify page and recorded alongside your experimental data.

Materials on this site are supplied strictly for in-vitro laboratory research. They are not offered for human or veterinary use. A research-use label does not by itself determine regulatory status; see the compliance page for official TGA guidance.

Purchasers must be 18 or over and are responsible for handling, storing and disposing of research materials in line with their institution's requirements and applicable Australian law.

Nothing on this page is medical advice, a dosing protocol, or a claim of therapeutic benefit. It summarises what the published research literature investigates.